|
Malignant neoplasm of breast
|
|
0.060 |
GeneticVariation
|
BEFREE |
Analyzing V57I genotypes showed a higher homozygote Val/Val genotype in patients compared with controls (76% vs 68%), whereas the frequency of heterozygous Val/Ile genotype was lower in patients (17%) than controls (30%), yielding a marginal association between breast cancer and Val/Val genotype (P = .048).
|
28906374 |
2017 |
|
Breast Carcinoma
|
|
0.060 |
GeneticVariation
|
BEFREE |
Analyzing V57I genotypes showed a higher homozygote Val/Val genotype in patients compared with controls (76% vs 68%), whereas the frequency of heterozygous Val/Ile genotype was lower in patients (17%) than controls (30%), yielding a marginal association between breast cancer and Val/Val genotype (P = .048).
|
28906374 |
2017 |
|
Breast Carcinoma
|
|
0.060 |
GeneticVariation
|
BEFREE |
Single nucleotide polymorphisms (SNPs) in CYP2E1 (rs6413432 and rs3813867), STK15 (rs2273535 and rs1047972) and XRCC1 (rs1799782 and rs25487) have been associated with breast cancer risk in a meta-analysis but any link in Southeast Asia, including Malaysia, remained to be determined.
|
26925658 |
2016 |
|
Malignant neoplasm of breast
|
|
0.060 |
GeneticVariation
|
BEFREE |
Single nucleotide polymorphisms (SNPs) in CYP2E1 (rs6413432 and rs3813867), STK15 (rs2273535 and rs1047972) and XRCC1 (rs1799782 and rs25487) have been associated with breast cancer risk in a meta-analysis but any link in Southeast Asia, including Malaysia, remained to be determined.
|
26925658 |
2016 |
|
Breast Carcinoma
|
|
0.060 |
GeneticVariation
|
BEFREE |
For V57I polymorphism, significant decreased breast cancer risk was found among Caucasians (recessive model: OR = 0.76, 95 % CI = 0.61-0.95; AA vs. GG: OR = 0.75, 95 % CI = 0.60-0.94; A vs. G: OR = 0.92, 95 % CI = 0.86-0.98).
|
25154511 |
2015 |
|
Malignant neoplasm of breast
|
|
0.060 |
GeneticVariation
|
BEFREE |
For V57I polymorphism, significant decreased breast cancer risk was found among Caucasians (recessive model: OR = 0.76, 95 % CI = 0.61-0.95; AA vs. GG: OR = 0.75, 95 % CI = 0.60-0.94; A vs. G: OR = 0.92, 95 % CI = 0.86-0.98).
|
25154511 |
2015 |
|
Malignant neoplasm of breast
|
|
0.060 |
GeneticVariation
|
BEFREE |
The present meta-analysis suggests that the STK15 F31I polymorphism is a strong predisposing risk factor for breast cancer, but no significant association existed between the STK15 V57I polymorphism and the risk of breast cancer.
|
23803310 |
2013 |
|
Breast Carcinoma
|
|
0.060 |
GeneticVariation
|
BEFREE |
The present meta-analysis suggests that the STK15 F31I polymorphism is a strong predisposing risk factor for breast cancer, but no significant association existed between the STK15 V57I polymorphism and the risk of breast cancer.
|
23803310 |
2013 |
|
Breast Carcinoma
|
|
0.060 |
GeneticVariation
|
BEFREE |
Two non-synonymous polymorphisms (F31I and V57I) have been associated with breast cancer risk in prior studies.
|
16411056 |
2006 |
|
Malignant neoplasm of breast
|
|
0.060 |
GeneticVariation
|
BEFREE |
Two non-synonymous polymorphisms (F31I and V57I) have been associated with breast cancer risk in prior studies.
|
16411056 |
2006 |
|
Malignant neoplasm of breast
|
|
0.060 |
GeneticVariation
|
BEFREE |
Individually, neither the F31I polymorphism [odds ratio (OR) 1.54; 95% confidence interval (CI) 0.96-2.47, comparing 31I with 31F homozygotes] nor the V57I polymorphism (OR 0.92; 95% CI 0.50-1.71, comparing 57I with 57V homozygotes) was significantly associated with breast cancer risk.
|
15271853 |
2004 |
|
Breast Carcinoma
|
|
0.060 |
GeneticVariation
|
BEFREE |
Individually, neither the F31I polymorphism [odds ratio (OR) 1.54; 95% confidence interval (CI) 0.96-2.47, comparing 31I with 31F homozygotes] nor the V57I polymorphism (OR 0.92; 95% CI 0.50-1.71, comparing 57I with 57V homozygotes) was significantly associated with breast cancer risk.
|
15271853 |
2004 |
|
Stomach Carcinoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
Our results revealed that AURKA (rs1047972 and rs911160), AURKB (rs2241909 and rs2289590) and AURKC (rs11084490) are associated with a higher risk of GC susceptibility.
|
31521144 |
2019 |
|
Malignant neoplasm of stomach
|
|
0.030 |
GeneticVariation
|
BEFREE |
Our results revealed that AURKA (rs1047972 and rs911160), AURKB (rs2241909 and rs2289590) and AURKC (rs11084490) are associated with a higher risk of GC susceptibility.
|
31521144 |
2019 |
|
Malignant Neoplasms
|
|
0.030 |
GeneticVariation
|
BEFREE |
We aimed to determine polymorphisms of F31I and V57I codons of AURKA gene and their association with cancer prognosis in patients compared with controls in an eastern population of Iran.A case-control study was conducted on specimens from 100 patients and 100 age- and gender-matched controls.
|
28906374 |
2017 |
|
Primary malignant neoplasm
|
|
0.030 |
GeneticVariation
|
BEFREE |
We aimed to determine polymorphisms of F31I and V57I codons of AURKA gene and their association with cancer prognosis in patients compared with controls in an eastern population of Iran.A case-control study was conducted on specimens from 100 patients and 100 age- and gender-matched controls.
|
28906374 |
2017 |
|
Malignant neoplasm of stomach
|
|
0.030 |
GeneticVariation
|
BEFREE |
Based on these results, we can conclude that AURKA rs1047972 and AURKC rs758099 polymorphisms could affect the risk of GC development.
|
27270838 |
2016 |
|
Stomach Carcinoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
Based on these results, we can conclude that AURKA rs1047972 and AURKC rs758099 polymorphisms could affect the risk of GC development.
|
27270838 |
2016 |
|
Primary malignant neoplasm
|
|
0.030 |
GeneticVariation
|
BEFREE |
The previous published data on the association between STK15 F31I and V57I polymorphisms and cancer risk remained controversial.
|
25154511 |
2015 |
|
Malignant Neoplasms
|
|
0.030 |
GeneticVariation
|
BEFREE |
The previous published data on the association between STK15 F31I and V57I polymorphisms and cancer risk remained controversial.
|
25154511 |
2015 |
|
Primary malignant neoplasm
|
|
0.030 |
GeneticVariation
|
BEFREE |
Aurora-A V57I (rs1047972) polymorphism and cancer susceptibility: a meta-analysis involving 27,269 subjects.
|
24598702 |
2014 |
|
Malignant Neoplasms
|
|
0.030 |
GeneticVariation
|
BEFREE |
Aurora-A V57I (rs1047972) polymorphism and cancer susceptibility: a meta-analysis involving 27,269 subjects.
|
24598702 |
2014 |
|
Malignant neoplasm of stomach
|
|
0.030 |
GeneticVariation
|
BEFREE |
The results suggest that 169G>A in AURKA is associated with progression of gastric cancer by affecting relative kinase activities of AURKA variants.
|
16412566 |
2006 |
|
Stomach Carcinoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
The results suggest that 169G>A in AURKA is associated with progression of gastric cancer by affecting relative kinase activities of AURKA variants.
|
16412566 |
2006 |
|
Liver carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
We found that carriers of the TT allele of the variant rs1047972 were at greater risk of HCC compared with wild-type (CC) carriers.
|
29333101 |
2018 |